OBI Pharma signs agreement with Abzena for ADC linker technology

Cambridge, UK-headquartered drug development technology and services provider Abzena plc, has signed a licensing agreement and a master services and clinical supply agreement with Taipei, Taiwan biotech OBI Pharma (TPEx: 4174) for its novel site-specific ThioBridge™ antibody drug conjugate (ADC) linker technology to develop OBI’s proprietary ADC, OBI-999 and a series of further ADCs as potential treatments for cancer.

Read more

BioBusiness Asia 2017 examines global trends, new technologies shaping healthcare

BioBusiness Asia, the two-day business-themed life sciences conference held annually in Taipei, Taiwan, recently concluded. A part of the week-long BioTaiwan festival of life science-focused events, the conference this year had a wide range of session themes with a particular emphasis on emerging technologies such as precision medicine, next generation sequencing, artificial intelligence (AI), synthetic biology, cancer immunotherapy, and digital health.

Read more

Taiwan joins forces with Insilico Medicine to apply AI to biomedical research

The Development Center for Biotechnology (DCB), the Medical and Pharmaceutical Industrial Technology Development Center (PITDC), and Taipei Medical University (TMU), three of Taiwan’s premier biomedical institutions, have teamed up with Baltimore-based Insilico Medicine to develop groundbreaking research in applied A.I. for biomedical science.

Read more

AOP Orphan and PharmaEssentia announce latest clinical results for Ropeginterferon alfa-2b in Polycythemia Vera

AOP Orphan Pharmaceuticals AG of Vienna, Austria (AOP Orphan) and Taipei, Taiwan-headquartered PharmaEssentia Corporation (TPEx: 6446) together announced the latest results from three clinical studies on Ropeginterferon alfa-2b for patients with Polycythemia Vera (PV) presented at the 22nd Congress of the European Hematology Association (EHA) in Madrid, Spain.

Read more